Novotech CEO invited to chair clinical trials
September 9, 2005 by admin
Filed under Company News, Company News 2005
Sept 9, 2005 – London, UK — Novotech, the largest Australian full-service contract research organization (CRO) – with offices also in the UK and USA- , has accepted the London based Pharmaceutical & Biotech Outsourcing Research & Development Expo & Conference’s [PABORD] invitation for Novotech CEO Alek Safarian to chair the Clinical Trials Session on September 14, 2005.
PABORD 05 [14-15 September, 2005] is the international exhibition and conference focused exclusively on promoting the strategic and business advantages of outsourcing solutions for pharmaceutical, biopharmaceutical and biotechnology companies active in the entire discovery and development value chain.
The Novotech chaired session will focus on the value of outsourcing and offshoring clinical trials, as well as the use of gene expression in trials and issues around risk assessment.
The session follows the keynote presentation by Kenneth Getz, Research Fellow Tufts Centre for the Study of Drug Development, USA, on Quantifying the impact of outsourcing on drug development performance.
Time: September 14, 2005 at 14.00-16.30
Venue: Olympia 2, London UK
Editors please note: Novotech CEO Alek Safarian will be available for interviews during the conference. Contact +44 (0)1753 722 02.8 and ask for Susan Fitzpatrick.
Safarian will also be meeting with industry executives and discussing the new Novotech RiskShare offering which guarantees massive savings on clinical trial costs for selected biotechs in return for drug license rights in Australia and New Zealand.
Novotech offers clinical trial sponsors a comprehensive clinical trial services package, including clinical trial management and monitoring, electronic data capture, analysis and reporting, data and project management, and regulatory affairs.
Novotech, which was this year awarded the prestigious “25 CROs to watch” status by premier market intelligence firm Life Science Insights (LSI), part of the IDC group, has been fielding the risk sharing concept among its US clients over the past year.
Alek Safarian, Novotech CEO said; “Novotech RiskShare is a smart way to get much greater return from R&D expenditure. It’s designed to be a classic win-win opportunity for many companies and compounds.”
According to the LSI report author, Life Science Insights Research Director, pharmaceutical outsourcing markets, Ellen Julian, Novotech was identified as a “25 to watch” because: “we believed their capabilities positioned them well for the near future… because they are niche, specialty, and local players with strengths in consulting, technology integration, and access to naïve patient populations.”
“Clinical research trials in Australia can begin in as little as 2-3 months from the initiation of the approval process and cost up to 30% less than comparable Western countries such as the U.S. and in Europe,” said Safarian.
Australian regulatory procedures are supportive of the clinical trial process, while the patient population was similar to the U.S in terms of lifestyle and disease characteristics, and responsive to participation in leading edge clinical trials.
In the past three years, Novotech has worked with more than 35 U.S.-based and European pharmaceutical and biotech companies.
The IDG Report is available. Click here
About Novotech – Unsurpassed Local Knowledge and Network:
Increasingly, U.S. companies are turning to Australia to expedite the pace, and reduce the cost, of clinical trials, while maintaining the high standard of research that U.S. authorities demand. A 2001 Ernst and Young benchmarking study found that clinical research costs may be as much as 30 percent lower in Australia than in the United States and Europe.
In addition, Australian regulatory procedures often enable a trial to begin in as little as 2-3 months from the initiation of the approval process. This compares favorably to usual timelines in major Western countries.
As the largest independent CRO in Australia, Novotech offers a level of flexibility and local knowledge that is virtually unmatched among other contract research organizations in the region. This has helped Novotech develop a strong client base in the United States and Europe.
Headquartered in Sydney, Novotech is focused on the Australian and New Zealand markets but has worldwide reach through the company’s subsidiary in the United Kingdom and through key external partnerships and strategic alliances in North America and other regions.
